Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of
$100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
NEW YORK, Nov. 2, 2012
NEW YORK, Nov. 2, 2012 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading
national securities law firm, is investigating potential securities fraud at
Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NasdaqCM: KERX).
(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )
The investigation focuses on whether the Company and its executives violated
federal securities laws with respect to its disclosures concerning perifosine,
an experimental drug that Keryx had been co-developing to treat those
suffering from colorectal cancer.
On April 2, 2012, Keryx announced the top-line data from the Perifosine X-PECT
Phase 3 Clinical Trial. The Company revealed that the trial for refractory
advanced colorectal cancer did not meet the primary endpoint of improving
overall patient survival versus capecitabine and a placebo. On this
disappointing news, Keryx share price plummeted from $4.98 on March 30, 2012
to $1.74 on April 2, 2012 – a decline of roughly 65 percent.
Request more information now by clicking here: www.faruqilaw.com/KERX. There
is no cost or obligation to you.
If you purchased Keryx stock or options between June 1, 2009 and April 1, 2012
and would like to discuss your legal rights, visit www.faruqilaw.com/KERX.
You can also contact us by calling Richard Gonnello or Francis McConville toll
free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to
email@example.com or firstname.lastname@example.org. Faruqi & Faruqi, LLP
also encourages anyone with information regarding Keryx's conduct to contact
the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter. We welcome the
opportunity to discuss your particular case. All communications will be
treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP
Press spacebar to pause and continue. Press esc to stop.